30. November 2016
Press Release: Zedira receives funding by the German Government for the development of transglutaminase inhibitors for the treatment of diabetic nephropathy
Read more | Document

30. November 2016
Pressemitteilung: Zedira erhält Fördermittel für die Entwicklung von Transglutaminase-Blockern zur Behandlung der diabetischen Nephropathie
Read more | Document

22. September 2016
Zedira supports 2nd International Factor XIII Workshop
Read more | Document

01. July 2016
Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
Read more | Document

01. July 2016
Pressemitteilung: Dr. Falk Pharma GmbH und Zedira GmbH starten klinische Phase 1b zur medikamentösen Behandlung der Zöliakie
Read more | Document

23. May 2016
Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
Read more | Document

20. April 2016
Zöliakie – weit mehr als ein bisschen Bauchschmerzen und Durchfall Von der Grundlagenforschung zur klinischen Entwicklung
Read more | Document

25. February 2016
Curious about your antibody or anti-serum?
Read more | Document

26. January 2016
Zedira supports Gordon Research Conference on "Transglutaminases in Human Disease Processes"
Read more | Document

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events  

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy